JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders

Do gene fusions characterize aggressive cytotoxic behavior of cutaneous T-cell lymphoma (CTCL)?In this single–cancer center case-series of 43 adult patients with CTCL with gene fusions, 38 (88%) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD) or overlap presentations; only 5 cases (11.6%) of aggressive CTCL were identified. Neither mutational burden, type, or fusion partner distinguished indolent from aggressive CTCL. fusions should not be interpreted unequivocally as aggressive markers in CTCL because it can be present in patients without aggressive cytotoxic disease; JAK2 may be a potentially therapeutic target in early MF and CD30-positive LPD.

Corresponding Author: Shamir Geller, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY 10021 (gellers@mskcc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.